You are here: Home » Markets » News
Business Standard

AstraZeneca Pharma hits fresh record high of Rs 4,489; stock surges 15%

The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period.

Topics
AstraZeneca | Buzzing stocks | Pharma stocks

SI Reporter  |  Mumbai 

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
AstraZeneca Plc, the company's parent firm, is expected to release initial data on whether a vaccine can stop people from getting the virus on September 15.

Continuing their northward movement, shares of Pharma India hit a fresh record high of Rs 4,489, up 15 per cent on the BSE on Monday, in an otherwise range-bound market, amid expectation that the company’s candidate, AZD1222, could be viewed as a frontrunner in a global race to deliver an effective vaccine to combat the Covid-19 virus.

At 03:05 pm, the stock was trading 13 per cent higher at Rs 4,411 on the BSE. In comparison, the S&P BSE Sensex was trading 0.36 per cent lower at 38,218 points. The stock of the pharmaceutical company was trading higher for the fifth straight day, surging 26 per cent during the period.

According to a Reuters report, Australia expects to receive its first batches of a potential Covid-19 vaccine in January, Australian Prime Minister Scott Morrison said on Monday, as the number of new daily infections in the country’s virus hotspot fell to a 10-week low. CLICK HERE TO READ FULL REPORT

Plc, the company's parent firm, is expected to release initial data on whether a vaccine can stop people from getting the virus on September 15. The drugmaker has pledged as many as 30 million doses to the UK by the end of the month.

Meanwhile, since August 18, 2020, the stock of Pharma has gained 35 per cent, after the company received import and market permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication. CLICK HERE FOR RELEASE


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 07 2020. 15:08 IST
RECOMMENDED FOR YOU
.